North America Autoimmune Disease Diagnostics Market share was valued at USD 5.5 billion in 2019 and is expected to witness 2.3% CAGR from 2020 to 2026.
Get more details on this report - Request Free Sample PDF
Growing prevalence of autoimmune diseases such as type 1 diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, grave’s disease, rheumatoid arthritis are a few diseases that will drive the market growth in the region positively. According to the National Institutes of Health, in 2017, around 23.5 million Americans were suffering from an autoimmune disease and the prevalence of autoimmune diseases is continously rising in the U.S. In addition, autoimmune diseases are considered as the second leading cause of chronic illnesses and thereby, causes a significant amount of financial burden on the healthcare providers and the government. Hence, this substantial increase in prevalence leads to higher demand for early diagnosis and treatment that further stimulate market growth in the future.
Rising awareness among patients pertaining to the autoimmune diseases is one of the major drivers for the regional market growth. The American Autoimmune Related Diseases Association (AARDA) has started the initiative of educating the public on prevalence rate, risk factors, and severe lack of awareness surrounding autoimmune diseases. AARDA launched several national awareness campaign related to autoimmune diseases to combat the lack of information associated with these diseases. That in turn, forms a significant factor for the high death rate and delayed diagnosis leading to increased financial burden. Furthermore, AARDA announced March as the National Autoimmune Disease Awareness Month. It launched the new media public service campaign (PSA) to encourage patients and create awareness among public about the 100 known autoimmune disorders. Hence, owing to these programs the market is expected to witness an upsurge in the coming years.
North America Market Share, By Product
The localized autoimmune disease diagnostics segment held USD 3.6 billion revenue size in 2019. Growing technological advancements in detecting localized autoimmune disorders such as crohn’s disease, graves’s disease and celiac disease is propelling business growth. Favourable government initiatives and growing patient awareness regarding localized autoimmune disorders are some other factors contributing to segmental revenue growth over the forecast period.
North America Market Value, By Country
U.S. autoimmune disease diagnostics market recorded USD 4.9 billion revenue size in 2019. The increasing prevalence and high disease burden in the united states is boosting research and development activities pertaining to the early diagnosis and better ways of treating autoimmune diseases rendering significant positive impact on regional growth. Furthermore, the adoption rates for lab automation technology is high in the region and its demand is increasing as automation will significantly reduce human errors in the diagnosis thereby increasing accuracy in detecting the disease. Hence, owing to these factors the U.S. autoimmune disease diagnostics market will witness the substantial growth over the forecast timeframe.
Competitive Market Share
Some of the major industry players involved in North America autoimmune disease diagnostics market include Abbott Laboratories, Beckman Coulter, Inc., Bio-Rad Laboratories, Hemagen Diagnostics, Inova Diagnostics, Inc., Quest Diagnostics, SQI diagnostics, F. Hoffmann-La Roche Ltd, Siemens Healthineers, and Crescendo Bioscience, Inc. Firms are adopting strategies such as novel product development and product approval to enhance their market presence as well as expand their offerings. For instance, in 2019, Roche announced that Food, Drug and Administration (FDA) has granted Breakthrough Therapy Designation to its monoclonal antibody Gazyva for adults suffering with lupus nephritis.
Autoimmune disease diagnostics industry started its evolution during the mid 20th century. Scientist and doctors across the globe acknowledged the existence of autoimmune diseases during the 20th century. During the initial years of the century autoimmune disease was viewed as biologically unbelievable. The discoveries of allergy and anaphylaxis were the first clues that the immune system was capable of self-harm. Subsequent advancements and development of the product led to the testing for the presence of anti-nuclear antibodies in the diagnosis of autoimmune disorders such as systemic lupus erythematosus and other systemic autoimmune rheumatic diseases (SARD). Large number of industry players in the U.S. such as Abbott Laboratories, Beckman Coulter, Inc., Bio-Rad Laboratories, Hemagen Diagnostics, Inova Diagnostics, Inc., Quest Diagnostics, SQI diagnostics, F. Hoffmann-La Roche Ltd, Siemens Healthineers, and Crescendo Bioscience, Inc. entered autoimmune disease diagnostics market that increased industry rivalry. Currently, countries in the region are implementing initiatives to control and reduce the burden of autoimmune disorders. Hence, increasing number of population affected with autoimmune diseases will augment the demand and development of North America autoimmune disease diagnostics industry in the forthcoming years.